MX336958B - Metodos y composiciones para modular la hemostasia. - Google Patents

Metodos y composiciones para modular la hemostasia.

Info

Publication number
MX336958B
MX336958B MX2012006836A MX2012006836A MX336958B MX 336958 B MX336958 B MX 336958B MX 2012006836 A MX2012006836 A MX 2012006836A MX 2012006836 A MX2012006836 A MX 2012006836A MX 336958 B MX336958 B MX 336958B
Authority
MX
Mexico
Prior art keywords
methods
hemostasia
modulate
compositions
variants
Prior art date
Application number
MX2012006836A
Other languages
English (en)
Inventor
Rodney M Camire
Original Assignee
Philadelphia Children Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philadelphia Children Hospital filed Critical Philadelphia Children Hospital
Publication of MX336958B publication Critical patent/MX336958B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a una variante del Factor Xa que modula la hemostasia que comprende al menos una mutación por substitución en los aminoácidos 41-179 y 235-488 de SEQ ID NO: 1, en donde el Asp en la posición 418 (posición 194 en el sistema de numeración de quimiotripsina) se sustituye con Asn o Glu.
MX2012006836A 2005-11-15 2006-03-21 Metodos y composiciones para modular la hemostasia. MX336958B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73668005P 2005-11-15 2005-11-15
PCT/US2006/060927 WO2007059513A2 (en) 2005-11-15 2006-11-15 Compositions and methods for modulating hemostasis

Publications (1)

Publication Number Publication Date
MX336958B true MX336958B (es) 2016-02-05

Family

ID=38049397

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2008006313A MX2008006313A (es) 2005-11-15 2006-03-21 Metodos y composiciones para modular la hemostasia.
MX2012006836A MX336958B (es) 2005-11-15 2006-03-21 Metodos y composiciones para modular la hemostasia.
MX2012006837A MX337059B (es) 2005-11-15 2008-05-15 Metodos y composiciones para modular la hemostasia.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2008006313A MX2008006313A (es) 2005-11-15 2006-03-21 Metodos y composiciones para modular la hemostasia.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2012006837A MX337059B (es) 2005-11-15 2008-05-15 Metodos y composiciones para modular la hemostasia.

Country Status (25)

Country Link
US (4) US8383386B2 (es)
EP (4) EP2431390B1 (es)
JP (4) JP5823088B2 (es)
KR (4) KR20160029135A (es)
CN (1) CN101356192B (es)
AU (1) AU2006315175B2 (es)
BR (1) BRPI0618654B1 (es)
CA (2) CA2971971A1 (es)
CR (1) CR9956A (es)
DK (1) DK1948690T3 (es)
EC (1) ECSP088452A (es)
ES (2) ES2549929T3 (es)
GT (1) GT200800065A (es)
IL (1) IL191310A (es)
MX (3) MX2008006313A (es)
MY (1) MY162181A (es)
NO (3) NO345177B1 (es)
NZ (1) NZ568108A (es)
PL (1) PL1948690T3 (es)
PT (1) PT1948690E (es)
RU (2) RU2008123398A (es)
SI (1) SI1948690T1 (es)
SV (1) SV2008002906A (es)
WO (1) WO2007059513A2 (es)
ZA (1) ZA200804026B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0816837B1 (pt) 2007-09-28 2022-10-18 Portola Pharmaceuticals, Inc Composições farmacêuticas, polipeptídeo isolado de duas cadeias e uso de uma composição farmacêutica
US8455439B2 (en) 2008-11-14 2013-06-04 Portola Pharmaceuticals, Inc. Antidotes for factor Xa inhibitors and methods of using the same in combination with blood coagulating agents
PT3604510T (pt) 2009-03-30 2025-06-24 Alexion Pharma Inc Antídotos para inibidores do fator xa e métodos de utilização dos mesmos
PT2453910T (pt) 2009-07-15 2016-12-07 Portola Pharm Inc Formulação de dose unitária de antídoto contra inibidores de fator xa para uso na prevenção de sangramento
BR112013008034A2 (pt) 2010-10-06 2016-06-14 Medimmune Ltd método para normalizar hemeostase comprometida
EP2760887B1 (en) 2011-09-30 2024-10-23 The Children's Hospital of Philadelphia Compositions and methods for modulating hemostasis
US9145552B2 (en) * 2012-07-25 2015-09-29 Catalyst Biosciences, Inc. Modified factor X polypeptides and uses thereof
EP2950813B1 (en) * 2013-01-31 2019-09-04 Pfizer Inc Compositions and methods for counteracting factor xa inhibition
FR3001729B1 (fr) * 2013-02-04 2015-03-06 Lab Francais Du Fractionnement Mutants du facteur x
JP6429885B2 (ja) 2013-09-24 2018-11-28 ファイザー・インク 組換えヒト凝固第ｘａ因子タンパク質の不均一集団を含む組成物
JP6629744B2 (ja) * 2013-11-01 2020-01-15 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ 第Ｘａ因子の半減期を延ばす組成物および方法
KR20160093731A (ko) * 2014-01-24 2016-08-08 화이자 인코포레이티드 뇌내 출혈을 치료하기 위한 조성물 및 방법
EP3744840A1 (en) 2014-05-26 2020-12-02 Academisch Ziekenhuis Leiden Prohemostatic proteins for the treatment of bleeding
US10676731B2 (en) 2014-08-19 2020-06-09 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor IX function
EP4566666A3 (en) 2016-07-27 2025-09-17 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor ix function
EP4453012A1 (en) 2021-12-22 2024-10-30 Royal College of Surgeons in Ireland A conjugate for use in localising a molecule to the vascular endothelium

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093699A (en) 1987-07-09 2000-07-25 The University Of Manitoba Method for gene therapy involving suppression of an immune response
WO1994017810A1 (en) 1993-02-12 1994-08-18 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
WO1994023744A1 (en) 1993-04-16 1994-10-27 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
WO1995005864A1 (en) 1993-08-27 1995-03-02 Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Convection-enhanced drug delivery
AT401270B (de) 1994-09-26 1996-07-25 Immuno Ag Verfahren zur quantifizierung von genomischer dna
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
EA001616B1 (ru) 1995-02-28 2001-06-25 Зе Риджентс Оф Зи Юнивесити Оф Кэлифоньэ Способ лечения болезни сердца, способ лечения недостаточности периферических сосудов и способ ограничения доставки и экспрессии трансгенной конструкции в определенном органе или структуре
AU2319497A (en) 1996-03-07 1997-09-22 Regents Of The University Of California, The Helper-free, totally defective adenovirus for gene therapy
AT405516B (de) * 1997-02-27 1999-09-27 Immuno Ag Faktor x-analoge mit modifizierter proteasespaltstelle
AT405517B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-deletionsmutanten und analoge davon
AT410216B (de) * 1999-08-10 2003-03-25 Baxter Ag Faktor x-analogon mit verbesserter aktivierbarkeit
AU2001249389A1 (en) 2000-03-22 2001-10-03 The Children's Hospital Of Philadelphia Modified blood clotting factors and methods of use
FR2831170B1 (fr) * 2001-10-19 2004-03-19 Inst Nat Sante Rech Med Proteines c modifiees activables directement par la thrombine
FR2841904B1 (fr) * 2002-07-03 2004-08-20 Inst Nat Sante Rech Med Analogues de facteurs x clivables par la thrombine
EP1728798A1 (en) 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
US8436144B2 (en) * 2008-12-19 2013-05-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Serine protease derivatives and uses in the prevention or the treatment of blood coagulation disorders

Also Published As

Publication number Publication date
KR20140115374A (ko) 2014-09-30
JP5957167B2 (ja) 2016-07-27
ECSP088452A (es) 2008-07-30
ZA200804026B (en) 2009-10-28
KR101600158B1 (ko) 2016-03-08
US20180251745A1 (en) 2018-09-06
JP2009515559A (ja) 2009-04-16
NO345177B1 (no) 2020-10-26
JP6236194B2 (ja) 2017-11-22
CN101356192B (zh) 2013-09-11
IL191310A (en) 2015-06-30
CR9956A (es) 2008-08-21
CA2971971A1 (en) 2007-05-24
US20160362673A1 (en) 2016-12-15
DK1948690T3 (da) 2014-09-01
KR20080078664A (ko) 2008-08-27
BRPI0618654A2 (pt) 2011-09-06
MX2008006313A (es) 2008-11-06
EP2423224B1 (en) 2015-08-12
AU2006315175B2 (en) 2013-02-07
HK1128699A1 (en) 2009-11-06
JP2014073127A (ja) 2014-04-24
EP1948690A2 (en) 2008-07-30
KR20160029135A (ko) 2016-03-14
KR101827569B1 (ko) 2018-02-09
NO20082182L (no) 2008-07-30
EP1948690B1 (en) 2014-06-11
NZ568108A (en) 2011-09-30
PL1948690T3 (pl) 2014-11-28
EP2423224A1 (en) 2012-02-29
CA2629491A1 (en) 2007-05-24
GT200800065A (es) 2008-11-03
NO20200670A1 (no) 2008-07-30
US20140120155A1 (en) 2014-05-01
CN101356192A (zh) 2009-01-28
JP2018033459A (ja) 2018-03-08
SV2008002906A (es) 2008-10-22
BRPI0618654A8 (pt) 2019-01-15
JP2016005464A (ja) 2016-01-14
KR101574042B1 (ko) 2015-12-03
PT1948690E (pt) 2014-09-08
US9896676B2 (en) 2018-02-20
RU2570547C2 (ru) 2015-12-10
AU2006315175A1 (en) 2007-05-24
RU2011130932A (ru) 2013-01-27
RU2008123398A (ru) 2009-12-27
SI1948690T1 (sl) 2014-09-30
WO2007059513A2 (en) 2007-05-24
BRPI0618654B1 (pt) 2021-10-19
HK1165444A1 (en) 2012-10-05
JP5823088B2 (ja) 2015-11-25
US9410137B2 (en) 2016-08-09
WO2007059513A3 (en) 2007-11-29
EP2431390B1 (en) 2015-08-12
US8383386B2 (en) 2013-02-26
NO20200671A1 (no) 2008-07-30
US20090175931A1 (en) 2009-07-09
EP2431390A1 (en) 2012-03-21
ES2496567T3 (es) 2014-09-19
CA2629491C (en) 2019-05-07
EP2431389A1 (en) 2012-03-21
ES2549929T3 (es) 2015-11-03
MX337059B (es) 2016-02-09
EP1948690A4 (en) 2009-06-17
JP6571735B2 (ja) 2019-09-04
KR20140005383A (ko) 2014-01-14
MY162181A (en) 2017-05-31

Similar Documents

Publication Publication Date Title
MX337059B (es) Metodos y composiciones para modular la hemostasia.
CR10213A (es) Moduladores de la proteína quinasa aurora
CY1113102T1 (el) Ενωσεις φαινυλπροπιοναμιδιου και η χρηση αυτων
CU20070160A7 (es) Pirrolopirazoles, inhibidores potentes de quinasa
NO20092637L (no) Fremgangsmater for behandling
CY1117833T1 (el) Νεες συνθεσεις και μεθοδοι για την αγωγη του καρκινου
NO20071127L (no) Triazoloftalaziner
CR11373A (es) COMPUESTOS DE TIENOPIRIMIDINA Y PIRAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE mTOR CINASA Y PI3 CINASA
EA200802008A1 (ru) Фармацевтические композиции
CY2014030I1 (el) Θεραπευτικες συνθεσεις που περιλαμβανουν ingenol-3-angelate
SV2009003434A (es) Inhibicion de arni de expresion de alfa-enac
CY2014011I2 (el) Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
CL2008000873A1 (es) Compuestos derivados de pirrolidin amidas; composicion farmaceutica que comprende dichos compuestos; y su uso para tratar trombosis.
ECSP088558A (es) Carbonilamino pirrolopirazoles, potentes inhibidores de quinasa
PL2215071T3 (pl) Proleki tetrahydrokannabinolu, kompozycje zawierające proleki tetrahydrokannabinolu i sposoby ich stosowania
EP2068864A4 (en) THERAPEUTIC USES OF UROLITHINES
CY1110648T1 (el) Ενωσεις τροπανιου
UY31484A1 (es) Piperidinas heteroaril-sustituidas
PL2214656T3 (pl) Kompozycje i sposoby wzmacniania odpowiedzi immunologicznej
BRPI0720211A2 (pt) Derivado de indanona, composição, e, uso de uma composição
CR11423A (es) NUEVOS INHIBIDORES DE sEH Y SU USO
EA200870515A1 (ru) Моноциклические гетероарильные соединения
EP1951050A4 (en) THERAPEUTIC COMPOSITIONS AND METHOD
UY30801A1 (es) Compuestos calciliticos
BRPI0820260A2 (pt) Composição anti-helmíntica e uso da composição